

ASX RELEASE

22 January 2018

RECEIPT OF SECURITIES IN NOXOPHARM LIMITED (ASX: NOX)

Sydney, 22 January 2018 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is pleased to announce that, pursuant to the collaboration with Noxopharm Limited (ASX: NOX) to support future development of NOX66, as announced to ASX on 27 December 2017, the Company has now been issued with the following securities by Noxopharm:

- 5,317,123 Fully Paid Ordinary Shares in Noxopharm Limited (ASX: NOX), voluntarily held in escrow until 14 June 2018; and
- 3,000,000 Unlisted Options over NOX stock, expiry 18 January 2020, and exercisable @ \$0.80 (NOXAT). These options are unable to be exercised prior to 18 July 2018.

The above securities have an estimated market value of approximately AU\$6.5 million on the date of issue.

[ENDS]

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates and a preclinical discovery program, and we are working to develop therapies across a range of oncology indications.

Our lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the most common and most aggressive form of primary brain cancer. Licensed from Genentech in late 2016, GDC-0084 entered a phase II clinical trial December 2017. Initial data is expected in late calendar 2018, and the study is expected to complete in 2021.

TRX-E-002-1 (Cantrixil), is a third-generation benzopyran molecule with activity against cancer stem cells, and is being developed to treat ovarian cancer. TRX-E-002-1 is currently undergoing a phase I clinical trial in Australia and the United States. Initial data is expected in the first half of calendar 2018.

Board of Directors

Mr Iain Ross Chairman, Non-Executive Director

Mr Bryce Carmine Non-Executive Director

Mr Steven Coffey Non-Executive Director

Dr James Garner Chief Executive Officer, Managing Director